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Abstract
Positron Emission Tomography using 18F-fluoro-deoxi-glucose (FDG-PET) is giving a new perspective in disease 
staging and therapeutic response evaluation in daily oncological practice. To understand better the biological behavior 
and therapeutic response of breast cancer, new tracers and targets of molecular imaging are under investigation. 
These tracers may lead to non-invasive evaluation of the main, leading therapeutic decision-maker properties 
of metastatic breast cancer such as receptor status, proliferation activity and therapy resistance, and could also 
become predictive markers in the early measurement of therapeutic response in the neoadjuvant treatment of locally 
advanced breast cancer. However, these new agents are currently not available in the daily practice; the preliminary 
results are promising.
Keywords: PET-CT, breast cancer; FLT-PET, FES-PET; therapeutic 
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Introduction
In the western world breast cancer is the most common malignancy 
and cause of cancer death in women second only to lung cancer [1]. Even 
though the incidence of breast cancer is rising in the last few decades, 
mortality appears to be declining [2], indicating a probable benefit 
from earlier detection and more effective treatments. Modern imaging 
techniques are excellent tools to reach this goal. Positron Emission 
Tomography (PET) is one of the imaging modalities which become 
successful not just in the staging of the disease, but in the therapeutic 
response evaluation, as well. The hybrid PET-CT imaging is a unique 
tool in the field of diagnostic imaging modalities: its main advantage 
is the ability to measure not just morphological, but also metabolical 
properties and even biological behavior of the tissues. These benefits 
increase the role of PET-CT diagnostics in oncology, especially in breast 
cancer diagnostics. 
In PET-CT imaging the most widely used radiotracer is the 
18F-fluoro-deoxi-glucose (FDG). FDG is a radio-labeled glucose 
analogue molecule which acts like a regular glucose until intracellular 
uptake via the glucose transporters (GLUTs) of the cell membrane. 
As the hexokinase enzyme phosphorylates the FDG, it is stuck in the 
cell, accumulating and reflecting the higher metabolic rate and glucose 
consumption of tumor tissues (the Warburg effect itself) [3]. With the 
additional CT imaging technique the sensitivity and specificity of FDG-
PET-CT imaging is become remarkable in the staging of the disease, 
the detection of distant metastases and tumor recurrence as well [4-8].
Although in most countries in the daily clinical practice only FDG 
is available for PET-imaging, but the evolving new PET-CT tracers 
can give a new perspective in the determination of stage and in the 
evaluation of therapeutic response of tumors [9,10]. 
In our paper we review these new pathways of radiotracer researches 
in PET-imaging. To understand the mainstream of these researches, the 
tracers were divided into three main groups: 
• Tracers in connection to the unique therapeutic agents of breast 
cancer, such as hormonal or anti-HER2 (Human Epidermal Growth 
Factor Receptor 2) therapies–specific breast cancer tracers
• Tracers which are–like FDG itself–related to cell proliferation and 
metabolism non-specifically for breast cancer, and 
• Tracers linked to other pathways of tumor metabolism, such as 
the markers and inhibitors of angiogenesis, or to growth factor receptor 
families. (mostly under investigation)
Hormone receptor imaging with PET-CT
As Oude Munning et al. [11] suggested hormone receptor imaging 
could become a reasonable choice in the diagnosis and evaluation of 
recurrent and/or metastatic hormone positive breast cancer due to 
the fact that hormone receptor expression can vary between primary 
tumor and its recurrence in nearly 30% of the cases or even more [12-
14]. Although it is possible to sample recurrent or metastatic tumors, 
in most cases sampling is troublesome or even impossible. For these 
patients a specific estrogen imaging method could be determinative for 
the later therapy giving the chance to analyze the whole tumor tissue 
with one imaging technique, avoid sampling errors and unnecessary 
delay in the appropriate treatment of cancer patients [15]–these are the 
guiding light of present and future researches with hormone receptor 
imaging techniques. 
Estrogen receptor imaging
16-α-[18F]-fluoro-17-β-estradiol (FES) is a suitable tracer for 
these goals. This radio-labeled ligand of the estrogen receptors (ER) 
was investigated since 1988 [16,17] and has been successful in the 
evaluation of hormone receptor status in breast carcinomas [18-20]. 
Further researches focused on the optimization of the imaging with 
FES PET by analyzing the blood clearance and its interactions with 
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sex hormone binding globulins (SHBGs) [21,22]. Peterson et al. [23] 
recently demonstrated the significance of lean body mass adjusted 
FES-SUV calculations (SUV=Standardized Uptake Value) and also 
underlined the importance of the SHBG levels to optimize FES 
imaging techniques. In therapy monitoring Dehdashti et al. [24] also 
found interesting correlations between the therapeutic response to the 
endocrine treatment and FES-uptake: patients who were responding 
to tamoxifen treatment showed higher initial FES uptake (and also 
metabolic flare phenomenon with FDG tracers after the initiation of 
the therapy) than non-responders [19,24-26]. Linden et al. [27] found 
similar results with 6 months of hormonal treatment (i.e., tamoxifen), 
but the connection between FES-uptake and response to treatment 
was higher in patients with luminal A molecular subtype (only ER 
positive) tumors than with luminar B (both HER2 and ER positive) 
ones. Moreover, Linden et al. further analyzed the efficiency of FES 
imaging during different ER-blocking treatments. With tamoxifen and 
fulvestran treatment the eventually detected decline of FES caused by 
the treatment were higher than the treatment-related decline due to 
estrogen-depleting aromatase-inhibitor therapies [28]. In conclusion–
as van Kruchten et al. [29] pointed out correctly–whole-body imaging 
of ER expression with FES-PET can become a valuable diagnostic 
modality but only if standard work-up is inconclusive, due to the 
possible variations and known limitations of FES scans [30]. A new 
agent, 4-fluoro-11β-methoxy-16α-[18F]-fluoro-estradiol (4FMFES) 
developed by Paquette et al. achieved higher specific tumor uptake and 
also better contrast, i.e. tumor-to-background ratio than FES [31].
Progesterone receptor imaging
21-[18F]fluoro-16-α-ethyl-19-norprogesterone (FENP) and 4-[18F]
fluoropropyl-tanaproget (FPTP) are developed to characterize the 
progesterone status of breast cancer patients [15]. Clinical studies 
with FENP [32] were not successful due to the high metabolism of 
the tracer (high hepatic uptake and non-specific bindings), but new 
agents, such as FPTP may overtake these difficulties [33]. Tanaproget is 
a non-steroidal progestin, binding highly specifically and sensitively to 
progesterone receptors which made it suitable as a potential agent for 
radio-labeling and using in PET imaging. Zhou et al. [34] investigated 
this agent in vitro and in vivo, and the early results indicated a potential 
benefit of FPTP in progesterone receptor imaging [35].
Moreover, Dehdashti et al. [36] also studied the uptake of a new 
agent, 21-[18F]-fluoro-16a, 17a-[(R)-(19-a-furylmethylidene)dioxy]-
19-norpregn-4-ene-3,20-dione (FFNP), a fluoro-labeled progesterone 
analogue.
They also found promising results with this agent, showing its 
safety and sensitivity to assess progesterone receptor status of women 
with newly diagnosed breast cancer.
Growth Factor Receptor Imaging
HER-2 receptor imaging
HER-2 is a member of the Epidermal Growth Factor Receptor 
(EGFR) family, which contains 4 transmembrane tyrosine kinase 
receptors. HER-2 receptor is over expressed in approximately 20% 
of all breast cancers. HER-2 over expression was identified as an 
indicator of poor prognosis and more aggressive disease [37-40]. HER-
2 amplification and receptor over expression is extremely important in 
the treatment decision of breast cancer patients: to select the suitable 
patients for the targeted treatment of HER-2 with the monoclonal 
antibody, trastuzumab. To identify and quantify these receptors with 
imaging modalities is a highly investigated area due to the same reasons 
mentioned earlier with hormone receptor imaging: i.e., that HER-
2 expression can vary during treatment and differ across metastatic 
lesions [11]. The main conception of the PET imaging of HER-2 
receptors is to label trastuzumab and its fragments with positron 
emitting isotopes [41]. 
From the experiments of Smith-Jones, who used Hsp90 (heat shock 
protein 90) inhibitors to decrease HER-2 expression in mice and to 
monitor the changing, 68Ga-DOTA-F(ab’)2-herceptin fragment PET was 
applied, successfully [42]. The 89Zr-labeled trastuzumab revealed to be 
also a suitable agent for HER2-imaging [43,44], and also seemed to be 
advantageous in metastatic, HER2-positive breast cancer patients. The 
feasibility study of Dijkers et al. [45]–performed in 14 metastatic breast 
cancer patients–demonstrated the good visualization of HER-2 positive 
lesions with an appropriate 50 mg dose of 89Zr-labeled trastuzumab in 
trastuzumab-naïve and 10 mg in pretreated patients. 
After the first preliminary results with zirconium labeled 
trastuzumab PET, the researchers of the ZEPHIR study [46] also chose 
to apply 89Zr-trastuzumab PET to measure the HER-2 expression 
before and after 3 cycles of T-DM1 treatment. T-DM1 is a trastuzumab-
emtasin conjugate which contains trastuzumab and a maytansin 
derivate, a potent cytotoxic agent from the Vinca-alkaloid family, an 
effective, but expensive drug in anti-HER2 treatment. The rationales 
for this interventional, open-label study were the facts that the early 
identification of non-responder patients to T-DM1 could be cost-
effective and help to avoid unnecessary side-effects by using 89Zr-
trastuzumab PET. The preliminary results of this study are expected to 
be published in the autumn of 2013, the end of the study will be in 2015 
[46]. 
A new molecule, a fluorine-18 labeled HER2-binding affibody, the 
N-(2-(4-[18F]fluoro-benzamido)ethyl)maleimide ([18F]FBEM) conjugated 
ZHER2:342-Cys is also a promising agent in HER2 imaging. Affibodies 
are highly stable proteins smaller than regular monoclonal antibodies, 
therefore easier penetrate in solid tumors with a rapid clearance from 
the blood-stream. Moreover the binding is unaffected by pretreatment 
with trastuzumab. This enables to use them as suitable carriers of 
radioisotopes. According to the preclinical studies [18F] FBEM 
conjugated ZHER2:342-Cys could be an optimal candidate for clinical 
applications [47-50]. However other randomized studies with larger 
number of enrolled patients will also be required to further analyze 
the significance of HER2-imaging in treatment planning and daily 
oncological practice.
HER-1 (EGFR) and IGF-1 receptor imaging
Other members of the epidermal growth factor receptor family 
are also showing significant correlations with the behavior of breast 
cancers, like HER1 (EGFR) over expression, which is more frequent 
in triple negative (estrogen, progesterone and also HER-2 negative) 
tumors [51,52]. The contribution of the over-expressed HER1 (EGFR) 
in the enhanced cell-proliferation in breast cancer by binding to the 
epidermal growth factor (EGF) or the transforming growth factor alpha 
(TGFα) was also reported by Meng et al. Therefore, antibody-based, 
affibody-based, or EGF-based molecular probes for EGFR imaging of 
breast cancer have been under investigation [53]. 
Type 1 insulin-like growth factor receptor (IGF-1R) is a 
transmembrane tyrosine kinase receptor which plays an important role 
in signaling cell survival and proliferation. Some preliminary studies 
also showed that IGF-1R-targeted therapy in breast cancer can be 
monitored by imaging of IGF-1R expression [53,54].
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Tumor proliferation imaging–“beyond FDG”
FDG is highly specific for increased glucose metabolism and 
measurement of the presence of viable tumor tissues in the body. 
Although to measure the exact proliferation of the tumors more specific 
tracers are also under investigation. These special tracer molecules 
are currently available to study therapeutic response and tumor 
proliferation by measuring the rate of the cell membrane synthesis, or 
increased amino-, and nucleic-acid usage. 
Amino-acid metabolism radiotracers
The pioneer of these molecules was the 11C-methionine [55], an 
essential amino-acid molecule used by every cell of the human body, 
especially tumor cells to nourish their enhanced protein synthesis. 
11C-methionine incorporates in the newly synthesized proteins, 
allowing the imaging of the increased protein metabolism of cancers. 
11C-methionine uptake correlates fairly with the tumor proliferation 
in breast cancer patients and seemed to be useful in the measurement 
of therapeutic response. Based on the studies of a Finnish group we 
can conclude that metabolic changes in the amino-acid metabolism 
detected by 11C-methionine-PET precede the clinical response [56,57].
Moreover, during the investigation the glutamine and glutamate 
metabolism of the tumors, the cystine/glutamate exchanger (xC-
transpoter, xCT) also becomes a target for radiotracer imaging. Koglin 
et al. [58] found excellent tumor visualization and high tumor-to-
backgorund ratios by using (4S)-4-(3-[18F]fluoropropyl)-L-glutamate 
(BAY 94-9392, also named [18F]-FSPG) in preclinical tumor models. In 
Baek et al. study, [18F]-FSPG showed promising results in the detection 
of breast tumors, however, the number of the examined patients (n=5) 
is limiting the value of these results [59]. Although we must underline 
the significance of these studies, due to the reason that [18F]-FSPG is 
also developed to quantify glutathione-based drug resistance and 
oxidative stress-induced signaling pathways in which system xCT plays 
an important role by exchanging and transporting cystein to the cell 
[59].
DNA-synthesis radiotracers
Pyrimidine analogues–like 11C-thymidine and 18F-fluoro-deoxi-
L-thymidine (FLT)–are also promising agents in PET imaging based 
on detecting cellular proliferation and enhanced nucleic acid usage 
of tumor cells which is believed to be more specific for tumor tissue 
than FDG. FLT-PET is already proved its suitability in the visualization 
of breast cancers [60,61] and evaluating the early changes after 
chemotherapy [62]. 
Moreover FLT-PET seems to be useful for predicting therapeutic 
response. Dittman et al. found promising results with FLT in response 
evaluation in their in vitro study [63], and–according to Pio et al.–FLT-
PET was also a successful imaging method for the response evaluation 
after one administered cycle of chemotherapy and was also predictive 
for the long-term efficacy of the therapy by showing correlation with 
the late changes of tumor markers [64]. Recently Jolles et al. [65] 
are investigating the role of dynamic FLT-PET in the neoadjuvant 
treatment of breast cancer in their ongoing phase II study–FLT-PET 
is performed before the initiation of therapy, after 1 cycle and also 
after the completion of the treatment, the recruitment for the study is 
nearly ended [15]. Furthermore, Lubberink et al. [66] in their similarly 
structured study with dynamic FLT-PET imaging in locally advanced 
breast cancer patients treated with neoadjuvant chemotherapy, 
compared the effectiveness of tumor-to-whole blood ratio (TBR) 
measurements with the semi quantitative SUV (Standardized Uptake 
Value) results and suggested that TBR may be preferred to SUV when 
using FLT-PET imaging [67]. In conclusion FLT-PET may play a role in 
prediction of response to therapy in breast cancer patients, but further 
investigations are needed [11].
Phospholipid synthesis radiotracers
18F-fluoro-ethyl-choline (FEC) and 11C-choline which are integrated 
in the membrane phospholipid synthesis and 11C-acetate, a marker of 
the lipid synthesis are currently used in the imaging of prostate cancer 
[68,69] and hepatocellular carcinomas [70]. 
The first study with 11C-choline PET in breast cancer was performed 
by Contractor et al. to detect and separate clinically aggressive tumor 
phenotypes in patients with ER positive breast cancer. With 11C-choline 
PET these tumors were visualized with good tumor-to-background 
ratio and the choline-uptake also correlated well with tumor grade [71]. 
These results were confirmed by Kenny et al. and also revealed that 
tumor response to trastuzumab therapy could be early assessed with 
choline-imaging only after one month treatment [72]. Contractor et 
al. [73] also found significant correlation between tumor proliferation 
and choline-uptake during PET scans, not just by investigating the 
correlations with the widely used pathological marker, the Ki-67 
labeling index, but the 11C-choline-uptake also correlated well with the 
proliferation measured by 18F-fluoro-thymidine PET [73]. Tateishi et al. 
also examined the correlation between FDG-uptake and 11C-choline-
uptake in breast cancer patients. Although 11C-Choline showed higher 
specificity for the detection of aggressive disease (the degree of mitosis 
was the only marker which was independently associated with higher 
SUV and TBR of 11C-choline-PET/CTs), but by any other pathological 
and biological properties of the tumors FDG and choline tracer showed 
similar uptake-profile [74]. Eventually we can conclude that now FDG 
should still be preferred in daily clinical practice than choline, due to its 
easier production and wider availability.
Angiogenesis imaging
Angiogenesis is the physiological process of forming new blood 
vessels which is the key of tumor growth; therefore it could be a 
potential target for PET imaging. 
VEGF-receptor
Radio-labeled anti-VEGF and Fab-fragments–like the earlier 
described tracers containing trastuzmuab–have been used for 
development of anti-angiogenesis imaging. 89Zr-labeled bevacizumab 
showed clear and specific tumor localization in human ovarian cancer 
models [75]. Nagengast et al. reported similar results with 18F-labeled 
ranibizumab, a Fab-fragment binding to VEGF [76,77], and also found 
good correlation between 89Zr-bevacizumab uptake and therapeutic 
response to anti-angiogenic treatment in vivo in mouse-model with 
ovarian cancer xenografts [78]. The early experiences in breast cancer 
are also promising with 89Zr-bevacizumab-PET-CT imaging, Gaykema 
et al. found significant correlation between VEGF-A levels and 89Zr-
bevacizumab uptake in 26 breast cancer patients [79].
Integrins
Integrins are cell adhesion receptors which are important in cell-
cell interactions. Integrin α
𝑣
β3 has been shown to strongly correlate 
with tumor angiogenesis, and it has over expression on both endothelial 
and tumor cells in breast cancer. Integrin imaging originally based on 
the use of argininge-glycine-aspartic acid (RGD) based radioligands. 
McParland et al. [80] tested first the [18F]-fluciclatide, also named [18F]-
AH111585 (AH111585 is a cyclic peptide containing RGD motif that 
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binds directly to integrin receptors such as α
𝑣
β3 with high affinity) in 
healthy volunteers to assess the safety and biodistribution of intergrin-
tracers, with encouraging results. Beer et al. examined the tumor uptake 
of α
𝑣
β3-selective PET tracer 18F-galacto-arginine-glycine-aspartic-acid 
(18F-galacto) RGD in sixteen patients with primary (𝑛=12) or metastatic 
breast cancer (𝑛=4) and they found that all the primary tumors and 
metastases were clearly identified [53,81].
Other potential molecular imaging tracers
To investigate the chemo resistance and metastatic potential of 
tumors further PET-tracers are also under investigation. The earlier 
mentioned role of (4S)-4-(3-[18F]fluoropropryl)-L-glutamate ([18F]
FSPG) [59] in the quantification of glutathione-based drug resistance 
is still under investigation. 1-[18F]fluoroelacridar could be a suitable 
tracer for P-glycoprotein and breast cancer resistance protein detection, 
and also have potential benefits in the better understanding of the 
blood-brain barrier and ATP-driven efflux transport mechanisms 
[82]. Moreover, there are under consideration tracers against markers 
of the cell proliferation and metastatic potential such as radio-labeled 
agents against tumor growth factor-β receptor, platelet-derived growth 
factor-β receptor etc., which are currently under development or tested 
in vitro [11].
Conclusions
Development of new tracers in PET imaging could open a door 
for better understanding of the biological behavior of breast cancer, 
especially metastatic lesions and evaluate the heterogeneity and 
evolution of metastatic disease, due to the fact that biological behavior 
of breast cancer can differ between primary tumor and the metastases. 
The main advantage of PET imaging is the chance to avoid sampling 
errors of metastatic disease and spare the patient from unnecessary 
treatment and side-effects due to the chance of evaluating the whole-
tumor with one single imaging test. PET imaging could enable repeated 
assessment of receptor status, proliferation activity and tumor viability 
in the near future. Subsequent imaging with different tracers could also 
be promising methods for these patients, but to apply these methods in 
the daily clinical practice, further investigations are needed.
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